DNAtrix and Merck announced a collaboration to combine oncolytic virus therapy and PD-1 inhibition – the two companies will collaborate in phase II clinical trials on a therapy to treat glioblastoma, an especially deadly cancer for which there is no cure. Continue reading
![](https://blogs.shu.edu/cancer/files/2014/07/cancerBiology180x110.jpg)